Literature DB >> 17889072

Seroprevalence of herpes simplex virus type 1 in children in the United States.

Fujie Xu1, Francis K Lee, Rhoda A Morrow, Maya R Sternberg, Kristina E Luther, Gary Dubin, Lauri E Markowitz.   

Abstract

OBJECTIVES: To describe HSV-1 seroprevalence in children in the United States and to examine factors associated with herpes simplex virus type 1 (HSV-1) infection in children. STUDY
DESIGN: Sera samples available from 2989 children age 6 to 13 years who participated in the National Health and Nutrition Examination Surveys (NHANES) 1999-2002 were tested for HSV-1 antibodies using a type-specific immunodot assay. HSV-1 seroprevalence in children age 12 to 13 years was compared with that reported in an earlier survey (NHANES 1988-1994).
RESULTS: Overall, HSV-1 seroprevalence in children age 6 to 13 years was 31.1% (95% confidence interval [CI], 28.6% to 33.9%). Seroprevalence increased with age, from 26.3% in 6- to 7-year-olds to 36.1% in 12-to 13-year-olds, and varied by race/ethnicity, birthplace, and poverty level. Among US-born children age 12 to 13 years, the point estimate of HSV-1 seroprevalence was lower in NHANES 1999-2002 than in NHANES 1988-1994 (34.3% vs 38.1%), but the differences were not statistically significant.
CONCLUSIONS: HSV-1 is a common infection in US children, with more than 25% infected by age 7. Race/ethnicity, birthplace, and poverty level are predictors for HSV-1 infection in children.

Entities:  

Mesh:

Year:  2007        PMID: 17889072     DOI: 10.1016/j.jpeds.2007.04.065

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  29 in total

Review 1.  Novel composite efficacy measure to demonstrate the rationale and efficacy of combination antiviral-anti-inflammatory treatment for recurrent herpes simplex labialis.

Authors:  Christopher M Hull; Myron J Levin; Stephen K Tyring; Spotswood L Spruance
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

2.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

Review 3.  Viral infections during pregnancy.

Authors:  Michelle Silasi; Ingrid Cardenas; Ja-Young Kwon; Karen Racicot; Paula Aldo; Gil Mor
Journal:  Am J Reprod Immunol       Date:  2015-01-13       Impact factor: 3.886

4.  Efficacy results of a trial of a herpes simplex vaccine.

Authors:  Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal
Journal:  N Engl J Med       Date:  2012-01-05       Impact factor: 91.245

5.  Maternal Antibodies to Herpes Virus Antigens and Risk of Gastroschisis in Offspring.

Authors:  Martha M Werler; Samantha E Parker; Klaus Hedman; Mika Gissler; Annukka Ritvanen; Heljä-Marja Surcel
Journal:  Am J Epidemiol       Date:  2016-11-17       Impact factor: 4.897

6.  Systemic Inflammation and Viral Exposure among Young Mexican American Women: Nativity-Related Differences.

Authors:  Natalya Rosenberg; Martha L Daviglus; Holli A DeVon; Chang Gi Park; Kamal Eldeirawi
Journal:  Ethn Dis       Date:  2017-04-20       Impact factor: 1.847

7.  A double-blind placebo-controlled study to evaluate valacyclovir alone and with aspirin for asymptomatic HSV-1 DNA shedding in human tears and saliva.

Authors:  Manish Kumar; James M Hill; Christian Clement; Emily D Varnell; Hilary W Thompson; Herbert E Kaufman
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-07-15       Impact factor: 4.799

8.  HSV, axonal transport and Alzheimer's disease: in vitro and in vivo evidence for causal relationships.

Authors:  Elaine L Bearer
Journal:  Future Virol       Date:  2012-09       Impact factor: 1.831

9.  Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells.

Authors:  Lynda A Morrison
Journal:  Virology       Date:  2008-04-14       Impact factor: 3.616

10.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.